Orphatec can be a privately held development-stage biotechnology business with headquarters in Cologne, Germany. In addition, Alexion has established a extensive research collaboration with essential MoCD researchers from Orphatec to accelerate development of the investigational therapy.?.. Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec Alexion Pharmaceuticals, Inc. announced that it offers purchased patents and property from Germany-based Orphatec Pharmaceuticals GmbH linked to an investigational therapy for sufferers with molybdenum cofactor deficiency Type A, a devastating ultra-rare genetic disorder seen as a severe brain damage and rapid loss of life in newborns.Clostridium difficile is normally a bacterium that can cause colitis and various other intestinal conditions. The U.S. FDA stated patients who develop diarrhea after taking these drugs should be checked for CDAD. The drugs, including Nexium, Prilosec, Prevacid, Others and Zegerid, fall right into a category known as proton pump inhibitors . They are recommended to treat acid reflux, stomach ulcers and additional conditions, and function by reducing the quantity of acid in the stomach. Related StoriesCombatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr ChakravarthyDeaths from avoidable risk elements: an interview with Dr Ali Mokdad, IHMEDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixPeople acquiring drugs that suppress gastric acid production may be at an elevated risk for intestinal bacterias infections said the agency.